NEEDHAM, Mass.--(BUSINESS WIRE)--AblaCor Medical Corporation announced today that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) on five additional patents for its CircumBlator™ AFib Catheter Ablation System to advance pulmonary vein isolation (PVI) ablation procedures for patients with atrial fibrillation (AFib)—the most common irregular heart rhythm and a potentially deadly disorder. When issued, AblaCor will have a total of nine patents issued for its CircumBlator system, with several more pending. Although AblaCor’s technology is designed to address AFib, the patent portfolio also has been developed to include additional medical procedures.
“AFib is a major international epidemic,” said Martin Sklar, CEO of AblaCor. ”CircumBlator is designed to overcome the drawbacks of other ablation technologies due to their unpredictability in producing durable, continuous, transmural lesions. In fact, recurrence of AFib after treatment with currently available technologies is reported in the scientific literature to be approximately 30 percent.” (Source: “Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients with Paroxysmal Atrial Fibrillation.” Circulation. 2015;132:1311-1319.)
AblaCor also announced that it has established a Scientific Advisory Board (SAB) with the appointment of prominent electrophysiologist Lawrence Rosenthal, MD, PhD, FACC, FHRS, who is Director of Electrophysiology Service and Professor of Medicine, UMass Memorial Medical Center. “Ablacor’s novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance,” said Dr. Rosenthal.